NCT05909098View on ClinicalTrials.gov

Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

November 30, 2028

Conditions
NK CellB-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Interventions
COMBINATION_PRODUCT

autologous NK cell

autologous NK cell

Trial Locations (1)

441000

EC of Xiangyang No.1 People's Hospital Hubei University of Medicine, Hubei

All Listed Sponsors
collaborator

Qingdao Haier Biotechnology Co.,Ltd.

UNKNOWN

lead

Xiangyang No.1 People's Hospital

OTHER

NCT05909098 - Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma | Biotech Hunter | Biotech Hunter